(24/7 MARKET NEWS) – Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced, after yesterday’s market close, that the FDAs approved REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation as detected by an FDA-approved test.
Rigel is trading at $0.895, up $0.211 (+30.89%), on over 9 million shares.
Its 52-week range is $0.64 to $3.515, with its next inflection points at $1.09 and $1.29.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.